Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$105.77M+1225.55%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Lisa Graver
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 1,279
- Beta
- 0.18
- Country
- LU
- Piotroski score
- 0 / 9 (Weak)
- Altman Z-score
- -1.11
Financials
Revenue
$105.77M+1225.5%Net Income
$-66.82MEBITDA
$-1.51MFree Cash Flow
$-47.65MEPS (diluted)
$-0.19Shares Outstanding (diluted)
356.82M+46.4%Operating Expenses
$65.41MCash & Debt
$142.75MReturn of Capital
$0.00Revenue by Segment (annual)
$12.20BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $586.32M | $27.92M | $0.10 |
| 2024 | $489.68M | $-231.86M | $-0.87 |
| 2023 | $91.43M | $-551.73M | $-2.43 |
| 2022 | $83.03M | $-513.58M | $-2.60 |
| 2021 | $36.77M | $-101.50M | $-3.25 |
| 2020 | $66.62M | $-170.04M | $-5.44 |
| 2019 | $31.92M | $-209.88M | $-0.86 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.15
- Implied price
- $7.49
- Return from $5.92
- 4.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $3.73 — -37.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 35 | 43 | 51 | 59 | 67 |
|---|---|---|---|---|---|
| -2.0% | -11.8% | -8.1% | -4.9% | -2.1% | 0.5% |
| 3.0% | -7.3% | -3.4% | -0.0% | 2.9% | 5.6% |
| 8.0% | -2.8% | 1.3% | 4.8% | 7.9% | 10.7% |
| 13.0% | 1.7% | 6.0% | 9.7% | 12.9% | 15.8% |
| 18.0% | 6.2% | 10.7% | 14.5% | 17.9% | 21.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
20-86.86%Social Signal Score
Mentions (10)
- Newsglobenewswire.com·1d ago·Negative
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech's biosimilar to Humira® Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech's two Reykjavik drug substance suites
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Alvotech (ALVO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Alvotech (ALVO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·36d ago·Negative
…cense Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations REYKJAVIK, Iceland, August 31, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT80, a proposed interchangeable biosimilar to Entyvio® (v…
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
Alvotech to present at upcoming investor conferences in September REYKJAVIK, ICELAND (August 27, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Robert Wessman, Founder and Chairman, and Dr. Balaji V. Prasad, Chief Strategy Officer, will participate in the upcoming investor conferences in September as follows:
View source ↗ - Newsglobenewswire.com·46d ago·Neutral
… for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets REYKJAVIK, Iceland, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical (TWSE Stock Code: 1795) covering two of Alvotech's candidates in the United States and selecte…
View source ↗ - Newsseekingalpha.com·46d ago·Negative
Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts Alvotech maintains at a Hold rating due to missed H1 2026 earnings and ongoing regulatory challenges, despite pipeline progress. Recent FDA CRLs for AVT05 and AVT06 were due to manufacturing issues, now addressed, with BLAs resubmitted and multiple approvals targeted for Q4 2026. AVT06, a biosimilar to EYLEA, has global commercialization rights secured post-November 2026, with patent disputes resolved and a large ma
View source ↗ - Newsmarketbeat.com·47d ago·Neutral
Alvotech Q2 Earnings Call Highlights Alvotech NASDAQ: ALVO said its first-half 2026 results reflected a temporary manufacturing slowdown tied to facility and quality-system improvements at its Reykjavik site, while management reaffirmed full-year revenue and adjusted EBITDA guidance and highlighted upcoming regulatory decisions and product launches.
View source ↗ - Newszacks.com·47d ago·Neutral
Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates Alvotech (ALVO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.14 per share a year ago.
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update REYKJAVIK, Iceland, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) ("Alvotech" or the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the first half of 2026 and provided a business update.
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update REYKJAVIK, ICELAND (August 19, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the first half of 2026 and provided a business update.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.03 per share
Typical surprise -1.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 19$-0.11 vs $-0.05miss
- Wed, May 6$-0.09 vs $-0.07miss
- Wed, Mar 18$-0.37 vs $-0.01miss
- Wed, Nov 12$-0.02 vs $-0.03beat
- Wed, Aug 13$0.14 vs $-0.05beat
- Wed, May 7$0.35 vs $-0.08beat
Estimates and results for ALVO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in ALVO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.